drugset / Trial / NCT03066648
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients, and to identify recommended doses for future studies.
Timeline
- Start
- 2017-07-06
- Primary completion
- 2023-09-08
- Completion
- 2023-09-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Decitabine | Small molecule | — | — |
| Subject | Sabatolimab | Monoclonal antibody | — | — |
| Subject | Spartalizumab | Monoclonal antibody | — | — |